Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 362 participants.
Also called NCT05293639
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 362 participants
- Sponsor
- Registry
-
NCT05293639
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States
- Registry status
- Completed
Technical summary
Registry record NCT05293639. Allocation not applicable; no masking; primary purpose treatment. Start 2022-04-18 (actual); primary completion 2023-12-11 (actual). Results posted on 2025-04-04.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System
- Acronym
- AdmIRE
- Condition
- Atrial Fibrillation
- Intervention (Device)
- Pulse Field Ablation
- Lead sponsor
- Biosense Webster, Inc.
Record details
- Record id
cardio:ct-nct05293639- Content hash
12b24ce8d979026c17b24f923a6d2c8ed53463829974009406b97f4442257fea